Logo image of MPLN

MULTIPLAN CORP (MPLN) Stock Fundamental Analysis

NYSE:MPLN - US62548M2098 - Common Stock

23.15 USD
-0.36 (-1.53%)
Last: 2/27/2025, 8:04:01 PM
23.15 USD
0 (0%)
After Hours: 2/27/2025, 8:04:01 PM
Fundamental Rating

2

Taking everything into account, MPLN scores 2 out of 10 in our fundamental rating. MPLN was compared to 35 industry peers in the Health Care Technology industry. MPLN has a bad profitability rating. Also its financial health evaluation is rather negative. MPLN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

MPLN had negative earnings in the past year.
MPLN had a positive operating cash flow in the past year.
In the past 5 years MPLN reported 4 times negative net income.
Each year in the past 5 years MPLN had a positive operating cash flow.
MPLN Yearly Net Income VS EBIT VS OCF VS FCFMPLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B

1.2 Ratios

MPLN has a Return On Assets of -31.95%. This is comparable to the rest of the industry: MPLN outperforms 50.00% of its industry peers.
Looking at the Return On Equity, with a value of -1958.81%, MPLN is doing worse than 81.58% of the companies in the same industry.
MPLN has a better Return On Invested Capital (1.58%) than 76.32% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MPLN is below the industry average of 6.79%.
Industry RankSector Rank
ROA -31.95%
ROE -1958.81%
ROIC 1.58%
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
MPLN Yearly ROA, ROE, ROICMPLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

MPLN's Operating Margin of 10.63% is amongst the best of the industry. MPLN outperforms 92.11% of its industry peers.
In the last couple of years the Operating Margin of MPLN has declined.
With an excellent Gross Margin value of 74.27%, MPLN belongs to the best of the industry, outperforming 84.21% of the companies in the same industry.
MPLN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 10.63%
PM (TTM) N/A
GM 74.27%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
MPLN Yearly Profit, Operating, Gross MarginsMPLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so MPLN is destroying value.
The number of shares outstanding for MPLN remains at a similar level compared to 1 year ago.
Compared to 5 years ago, MPLN has less shares outstanding
Compared to 1 year ago, MPLN has a worse debt to assets ratio.
MPLN Yearly Shares OutstandingMPLN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200M 400M 600M
MPLN Yearly Total Debt VS Total AssetsMPLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

Based on the Altman-Z score of -0.30, we must say that MPLN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.30, MPLN perfoms like the industry average, outperforming 47.37% of the companies in the same industry.
A Debt/Equity ratio of 53.67 is on the high side and indicates that MPLN has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 53.67, MPLN is doing worse than 81.58% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 53.67
Debt/FCF N/A
Altman-Z -0.3
ROIC/WACC0.25
WACC6.29%
MPLN Yearly LT Debt VS Equity VS FCFMPLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B 5B

2.3 Liquidity

MPLN has a Current Ratio of 0.82. This is a bad value and indicates that MPLN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.82, MPLN is not doing good in the industry: 76.32% of the companies in the same industry are doing better.
A Quick Ratio of 0.82 indicates that MPLN may have some problems paying its short term obligations.
With a Quick ratio value of 0.82, MPLN is not doing good in the industry: 71.05% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.82
MPLN Yearly Current Assets VS Current LiabilitesMPLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

MPLN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1059.83%.
Looking at the last year, MPLN shows a decrease in Revenue. The Revenue has decreased by -3.21% in the last year.
The Revenue has been decreasing by -1.09% on average over the past years.
EPS 1Y (TTM)-1059.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-327%
Revenue 1Y (TTM)-3.21%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%-4.9%

3.2 Future

Based on estimates for the next years, MPLN will show a very strong growth in Earnings Per Share. The EPS will grow by 36.67% on average per year.
The Revenue is expected to grow by 2.09% on average over the next years.
EPS Next Y87.02%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.75%
Revenue Next 2Y2.09%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MPLN Yearly Revenue VS EstimatesMPLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M 1B
MPLN Yearly EPS VS EstimatesMPLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 0 -20 -40 -60 -80

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MPLN. In the last year negative earnings were reported.
Also next year MPLN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MPLN Price Earnings VS Forward Price EarningsMPLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

94.74% of the companies in the same industry are more expensive than MPLN, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.19
MPLN Per share dataMPLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200

4.3 Compensation for Growth

MPLN's earnings are expected to grow with 36.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.67%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MPLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MULTIPLAN CORP

NYSE:MPLN (2/27/2025, 8:04:01 PM)

After market: 23.15 0 (0%)

23.15

-0.36 (-1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)02-25 2025-02-25/bmo
Earnings (Next)05-06 2025-05-06
Inst Owners47.86%
Inst Owner Change-20.59%
Ins Owners6%
Ins Owner Change0%
Market Cap375.03M
Analysts77.78
Price Target13.94 (-39.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.46%
Min EPS beat(2)-73.58%
Max EPS beat(2)14.65%
EPS beat(4)2
Avg EPS beat(4)-370.31%
Min EPS beat(4)-1467.36%
Max EPS beat(4)45.02%
EPS beat(8)5
Avg EPS beat(8)-168.93%
EPS beat(12)6
Avg EPS beat(12)-282.74%
EPS beat(16)9
Avg EPS beat(16)-181.58%
Revenue beat(2)0
Avg Revenue beat(2)-3.09%
Min Revenue beat(2)-3.29%
Max Revenue beat(2)-2.88%
Revenue beat(4)0
Avg Revenue beat(4)-4.72%
Min Revenue beat(4)-6.88%
Max Revenue beat(4)-2.88%
Revenue beat(8)2
Avg Revenue beat(8)-2.62%
Revenue beat(12)3
Avg Revenue beat(12)-3.01%
Revenue beat(16)6
Avg Revenue beat(16)-1.99%
PT rev (1m)26.15%
PT rev (3m)24.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25.28%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.98%
Revenue NQ rev (1m)-0.56%
Revenue NQ rev (3m)2.01%
Revenue NY rev (1m)-0.41%
Revenue NY rev (3m)-0.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.4
P/FCF N/A
P/OCF 3.48
P/B 4.46
P/tB N/A
EV/EBITDA 9.19
EPS(TTM)-69.59
EYN/A
EPS(NY)-9.03
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)6.64
OCFY28.7%
SpS57.45
BVpS5.19
TBVpS-280.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.95%
ROE -1958.81%
ROCE 2%
ROIC 1.58%
ROICexc 1.59%
ROICexgc 26.88%
OM 10.63%
PM (TTM) N/A
GM 74.27%
FCFM N/A
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
ROICexc(3y)2.48%
ROICexc(5y)N/A
ROICexgc(3y)66.67%
ROICexgc(5y)N/A
ROCE(3y)3.05%
ROCE(5y)N/A
ROICexcg growth 3Y-40.96%
ROICexcg growth 5Y-27.14%
ROICexc growth 3Y-26.84%
ROICexc growth 5Y-14.89%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
F-Score3
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 53.67
Debt/FCF N/A
Debt/EBITDA 8.49
Cap/Depr 27.34%
Cap/Sales 12.69%
Interest Coverage 0.31
Cash Conversion 20.27%
Profit Quality N/A
Current Ratio 0.82
Quick Ratio 0.82
Altman-Z -0.3
F-Score3
WACC6.29%
ROIC/WACC0.25
Cap/Depr(3y)25.06%
Cap/Depr(5y)22.79%
Cap/Sales(3y)10.77%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1059.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-327%
EPS Next Y87.02%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.21%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%-4.9%
Revenue Next Year0.75%
Revenue Next 2Y2.09%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-41.76%
EBIT growth 3Y-37.5%
EBIT growth 5Y-23.25%
EBIT Next Year144.41%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-116.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.33%
OCF growth 3Y-35.69%
OCF growth 5Y-17.66%